

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	CAMBIUM BIO LIMITED
ABN	13 127 035 358

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Yu-Hung Sebastian Tseng
Date of last notice	11 April 2024

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct and Indirect
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	Zheng Yang Biomedical Technology Limited 93,381,212 Ordinary Shares
Date of change	28 June 2024
No. of securities held prior to change	Yu-Hung Sebastian Tseng 6,296,648 ordinary shares Zheng Yang Biomedical Technology Limited - 93,381,212 Ordinary Shares
Class	Fully paid ordinary shares
Number acquired	Yu-Hung Sebastian Tseng 17,546,938 ordinary shares Zheng Yang Biomedical Technology Limited - 175,469,372 Ordinary Shares
Number disposed	N/A

+ See chapter 19 for defined terms.

Appendix 3Y

Change of Director's Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	Yu-Hung Sebastian Tseng \$105,282 Zheng Yang Biomedical Technology Limited \$1,052,816
No. of securities held after change	Yu-Hung Sebastian Tseng 23,843,586 ordinary shares Zheng Yang Biomedical Technology Limited 268,850,584 Ordinary Shares
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Conditional right to subscribe for shares

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	Placement confirmation letters as announced to the market on 5 April 2024
Nature of interest	Conditional right to subscribe for shares pursuant to Tranche 2 of the placement
Name of registered holder (if issued securities)	N/A
Date of change	28 June 2024
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	Yu-Hung Sebastian Tseng 6,296,648 ordinary shares Zheng Yang Biomedical Technology Limited 93,381,212 Ordinary Shares
Interest acquired	N/A
Interest disposed	Subscription for shares pursuant to Tranche 2 of the placement settled on 28 June 2024. Accordingly, all of the interests under the contracts have been disposed.
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	Yu-Hung Sebastian Tseng \$105,282 Zheng Yang Biomedical Technology Limited \$1,052,816
Interest after change	Nil.

+ See chapter 19 for defined terms.

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	Yes
If so, was prior written clearance provided to allow the trade to proceed during this period?	Yes
If prior written clearance was provided, on what date was this provided?	28 June 2024

⁺ See chapter 19 for defined terms.